The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
High treatment burden in adults with cystic fibrosis: Challenges to disease self-management
Open accessAbstract
Background More aggressive management of cystic fibrosis (CF), along with the use of new therapies, has led to increasing survival. Thus, the recommended daily treatment regimens for most CF adults are complex and time consuming. Methods In the Project on Adult Care in CF (PAC-CF), an ongoing longitudinal study of CF adults, we assessed self-reported daily treatment activities and perceived treatment burden as measured by the CF Questionnaire-Revised (CFQ-R), a disease-specific quality of life measure. Results Among the 204 respondents, the median number of daily therapies reported was 7 (IQR 5-9) and the mean reported time spent on treatment activities was 108 minutes per day (SD 58 minutes). Respondents reported a median of 3 inhaled and 3 oral therapies on the day prior to the survey. Only 49% reported performing airway clearance (ACT) on that day. There were no differences in the number of medications or the time to complete therapies based on gender, age or FEV1. The mean CFQ-R treatment burden domain score was 52.3 (SD 22.1), with no significant differences in the treatment burden based on age or FEV1. In a multivariable model controlling for age, gender, and FEV1, using 2 or more nebulized medications and performing ACT for ≥30 minutes were significantly associated with increased treatment burden. Conclusion The level of daily treatment activity is high for CF adults regardless of age or disease severity. Increasing number of nebulized therapies and increased ACT time, but not gender, age, or pulmonary function, is associated with higher perceived treatment burden. Efforts to assess the effects of high treatment burden on outcomes such as quality of life are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A minimum of one to three nebulised treatments per day are usually prescribed, depending on an individual's characteristics (Hoo 2016), with treatments taking an average of 41 minutes per day (Sawicki 2009).”
From Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis (2023) · cites this paper as Sawicki 2009
The cited source says what the claim attributes to it.
In the citing paper
“with one study finding the average adult with CF spends two hours per day on CF care (1).”
From Virtual monitoring in CF – the importance of continuous monitoring in a multi-organ chronic condition (2023) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,671
Leventhal, H., Diefenbach, M., & Leventhal, E. A. (1992) · Cognitive Therapy and Research · doi:10.1007/bf01173486 · Cited by 1,573
Cystic Fibrosis Pulmonary Guidelines
Flume, P. A., O'Sullivan, B. P., Robinson, K. A., Goss, C. H., Mogayzel, P. J., Willey‐Courand, D. B., Bujan, J., Finder, J. D., Lester, M., Quittell, L. M., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-664oc · Cited by 1,024
Predictive 5-year survivorship model of cystic fibrosis
Liou, T. G., Adler, F. R., FitzSimmons, S. C., Cahill, B. C., Hibbs, J. R., & Marshall, B. C. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.4.345 · Cited by 749
Mucus Clearance and Lung Function in Cystic Fibrosis with Hypertonic Saline
Donaldson, S. H., Bennett, W. D., Zeman, K. L., Knowles, M. R., Tarran, R., & Boucher, R. C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043891 · Cited by 689
Yankaskas, J. R., Marshall, B. C., Sufian, B. S., Simon, R. H., & Rodman, D. M. (2004) · CHEST Journal · doi:10.1378/chest.125.1_suppl.1s · Cited by 574
Development and Validation of the Cystic Fibrosis Questionnaire in the United States
Quittner, A. L., Buu, A., Messer, M. A., Modi, A. C., & Watrous, M. L. (2005) · CHEST Journal · doi:10.1378/chest.128.4.2347 · Cited by 525
Barriers to Treatment Adherence for Children with Cystic Fibrosis and Asthma: What Gets in the Way?
Modi, A. C., & Quittner, A. L. (2006) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsj096 · Cited by 301
Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety
Geller, D. E., Konstan, M. W., Smith, J. J., Noonberg, S. B., & Conrad, C. (2007) · Pediatric Pulmonology · doi:10.1002/ppul.20594 · Cited by 195
Determinants of adherence in adults with cystic fibrosis
Kettler, L. J. (2002) · Thorax · doi:10.1136/thorax.57.5.459 · Cited by 147
Patient-reported Outcomes in Cystic Fibrosis
Goss, C. H., & Quittner, A. L. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200703-039br · Cited by 124
Ziaian, T., Sawyer, M. G., Reynolds, K. E., Carbone, J. A., Clark, J. J., Baghurst, P., Couper, J., Kennedy, D., Martin, A. J., STAUGAS, R., et al. (2006) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2006.00943.x · Cited by 108
Adherence of adult cystic fibrosis patients with airway clearance and exercise regimens
White, D., Stiller, K. R., & Haensel, N. (2006) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2006.06.006 · Cited by 71
Adults with cystic fibrosis report important and unmet needs for disease information
Sawicki, G. S., Sellers, D. E., McGuffie, K., & Robinson, W. M. (2007) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2007.03.004 · Cited by 50
Self-citationBoyle, M. (2003) · CHEST Journal · doi:10.1378/chest.123.1.3 · Cited by 18
Flagged first, then by citations
Cited by
Sorted by citations
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105787108 · Cited by 1,088
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- CFTR Mutation
Accurso, F. J., Rowe, S. M., Clancy, J. P., Boyle, M., Dunitz, J., Durie, P. R., Sagel, S. D., Hornick, D. B., Konstan, M. W., Donaldson, S. H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909825 · Cited by 803
Sawicki, G. S., Lukens-Bull, K., Yin, X., Demars, N., Huang, I.-C., Livingood, W., Reiss, J., & Wood, D. (2011) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsp128 · Cited by 592
Self-citationRatjen, F. A., Bell, S. C., Rowe, S. M., Goss, C. H., Quittner, A. L., & Bush, A. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.10 · Cited by 575
Quittner, A. L., Abbott, J., Georgiopoulos, A. M., Goldbeck, L., Smith, B., Hempstead, S. E., Marshall, B., Sabadosa, K. A., & Elborn, S. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207488 · Cited by 465
Metadata
- Authors
- Sawicki, G. S., Sellers, D. E., & Robinson, W. M.
- Affiliations
- Boston Children's Hospital (US)
- Education Development Center (US)
- Corresponding author
- Sawicki, Gregory S.
- Venue
- Journal of Cystic Fibrosis
- Publisher
- Elsevier BV
- Published
- 2009-03
- Volume
- 8
- Issue
- 2
- Pages
- 91-96
- ISSN
- 1569-1993 (ISSN-L)
- PMC
- PMC2680350
- OpenAlex
- W1976264709
- Semantic Scholar
- 6f4fe4eb5aa680de9ed1e2a38ba023699f8c2d53
- Cited by
- 498
- References
- 15
- Citations by year
- 2026: 15 · 2025: 25 · 2024: 29 · 2023: 41 · 2022: 46 · 2021: 32 · 2020: 35 · 2019: 35 · 2018: 30 · 2017: 39 · 2016: 25 · 2015: 37 · 2014: 29 · 2013: 23 · 2012: 15
- FWCI
- 12.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Cystic Fibrosis (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01 HL72938, R01HL072938)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Health Sciences › Nursing › Research and Theory › Nursing care and research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- treatment burden, disease self-management, adults with cystic fibrosis, airway clearance, quality of life, lung function
- MeSH terms
- Adult, Age Factors, Cystic Fibrosis, Female, Humans, Longitudinal Studies, Male, Quality of Life, Surveys and Questionnaires, Respiratory Therapy, Self Care, Severity of Illness Index, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
